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International Symposium of Intensive Care and Emergency Medicine (ISICEM), 20-
23 march 2018, Brussels, Belgium. 
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Abstract:  
Background: Sepsis profoundly alters immune homeostasis. Cytokine release after 
whole blood lipopolysaccharide (LPS)-stimulation reflects cell function across 
multiple immune cell classes and represents the immune response to LPS. The main 
goal of this study was to evaluate the prognostic value of ex vivo stimulation of whole 
blood with LPS in sepsis. 
 
Methods: Blood was drawn on day 1 and day 7 after admission, and stimulated ex 
vivo with LPS. Tumour necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6 and IL-10 were 
measured with and without stimulation. Our primary outcome measure was the 
persistence of at least one organ dysfunction at day 7. Organ dysfunction was 
defined according to the SOFA components by a score >=2. 
 
Results: Forty-nine patients with sepsis from a 21-bed intensive care unit, and 23 
healthy volunteers were enrolled. The blood of septic patients was less responsive to 
ex vivo stimulation with LPS than that of healthy controls at day 1 and 7, as 
demonstrated by lower TNF-α, IL-1β, IL-6 and IL-10 release. Persistent organ 
dysfunction was more frequent in patients with lower IL-10 release at day 1 but such 
an association was not found for pro-inflammatory cytokines. A persistent low IL-10 
release at day 7 was also associated with persistent organ dysfunction.  
 
Conclusion: These data suggest that the capacity to produce IL-10 in response to 
whole blood ex vivo stimulation early in sepsis, as well as persistent low IL-10 
response over time, may help in prognostication and patient stratification. These 
results will need to be confirmed in future studies.  
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1. Introduction 
 
Immune dysregulation is now a well-recognised phenomenon in Sepsis [1,2]. 
Improvements in critical care have increased the number of patients who survive the 
initial hyper-inflammatory phase of sepsis, but also increased the frequency of a 
chronic critical illness named persistent inflammation, immunosuppression and 
catabolism syndrome (PICS). PICS has been associated with prolonged intensive 
care unit (ICU) stays, moderate organ dysfunction, secondary infection, requirement 
for life support and protein catabolism [3]. Several biomarkers of immunosuppression 
in sepsis have been proposed to identify the subset of these patients who might 
benefit from of immune therapies [4,5]. The most studied of these have been human 
leukocyte antigen (HLA)-DR expression on monocytes, and Tumour Necrosis Factor 
(TNF)- release in whole blood lipopolysaccharide (LPS)-stimulation assays. Indeed, 
both decreased HLA-DR expression and decreased release of TNF-α after ex-vivo 
whole blood LPS-stimulation are associated with higher morbidity and mortality in 
critically ill patients [5-11]. While cell surface HLA-DR expression in monocytes may 
be considered a phenotypic marker of sepsis severity, cytokine release after whole 
blood LPS-stimulation reflects cell function across multiple immune cell classes, and 
represents the immune response to LPS [12,13]. Ex vivo whole blood LPS-stimulated 
TNF- release has been evaluated as a prognostic marker in critically ill patients in a 
variety of clinical situations, including sepsis patients, and with a range of clinical 
endpoints [5,6,10,11,14-19]. Although several authors have studied the release of 
other cytokines, such as interleukin (IL)-1, IL-6, or IL-10, after ex vivo whole blood 
LPS stimulation in sepsis [20-23], few have examined the prognostic value of the 
release of these cytokines in septic patients after ex vivo whole blood LPS 
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stimulation [14,16,17]. We aim, therefore, to examine the prognostic value of release 
of TNF-, IL-1, IL-6, and IL-10 after LPS whole blood stimulation measured within 
the 24 hours and one week after admission in ICU in patients with severe sepsis and 
septic shock.  
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2. Materials and methods 
 
This prospective observational pilot study was performed between November 2012 
and September 2014 in a 21-bed ICU at the University Hospital of Rennes (France). 
The study was approved by the local institutional ethics committee on June 12, 2012 
(Comité d’éthique, Centre Hospitalier Universitaire de Rennes, avis n°12-23, 
Chairperson: Dr Vincent MOREL) and informed consent was obtained from all 
participants or their next of kin. 
2.1. Study population  
Adults patients admitted in the ICU with a first episode of severe sepsis or septic 
shock were eligible. Severe sepsis and septic shock were defined based on the 
criteria proposed by the American College of Chest Physician/Society of Critical Care 
Consensus Conference Committee [24]. Patients who were pregnant or lactating, 
receiving immunosuppressive drugs, or who had a history of hematologic malignancy 
were excluded. 
2.2. Healthy control 
Twenty-three healthy volunteers without medical history were recruited (mean age 33 
years, sex ratio M/F 0.9) and informed consent was obtained from all participants.   
2.3. Blood samples and ex vivo LPS-stimulation 
For each patient, 15 mL of whole blood were collected in heparin-tubes within the 
first 24 hours of ICU admission (day 1), and then 7 days after ICU admission (day 7) 
if the patient was still in the study hospital. Within one hour of collection, blood was 
aliquoted in 96-well microplates under sterile conditions and incubated for 30 minutes 
at 37°C in an atmosphere of 5% CO2 and 95% air [25]. At the end of the incubation 
period, LPS from Escherichia Coli O55:B5 (product number L2880, Sigma-Aldrich) 
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was added in stimulated wells at 10 µg/mL, whereas un-stimulated wells received a 
sterile saline vehicle only (NaCl 0.9%). After 24h incubation, the plasma supernatants 
were gently transferred in polypropylene micro tubes and stored at -80°C until 
cytokine assay.  
2.4. Cytokine assay 
The concentrations of TNF-, IL-1, IL-6 and IL-10 were determined via enzyme 
linked-immunosorbent assay (ELISA) according to the manufacturer instructions 
(Bio-Techne, R&D systems, France). A standard concentration-response curve was 
run on each microplate to allow determination of cytokine levels in samples. Cytokine 
concentrations in each sample were determined using an automatic plate reader 
associated with Genesis software (LabSystems Spectrophotometer, Cambridge, UK) 
and data were expressed in pg/mL.  
2.5. Data collection 
The following data were collected: age, sex, ICU admission characteristics, 
comorbidities and overall severity of pre-existing underlying disease based on 
McCabe’s classification [26], information regarding the site, source and type of initial 
infection, presence of vasopressors infusion, mechanical ventilation and renal 
replacement therapy, delay between hypotension and first antimicrobial therapy, use 
of low-dose corticosteroids, acquisition of health-care associated infection in ICU, 
length of ICU and study hospital stay, 28- and 90-day mortality. The severity of the 
illness was assessed within 24 hours of ICU admission using the Simplified Acute 
Physiology Score (SAPS) II. The Sequential Organ Failure Assessment (SOFA) 
score and white blood cell count were assessed within the first 24 h and 7 days after 
the admission in ICU if the patient was still in the study hospital.  
2.6. Outcome definitions 
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Our primary outcome measure was the persistence of at least one organ dysfunction 
at day 7. Organ dysfunction or failure was defined according to the SOFA 
components by a score >=2. The secondary outcomes were health-care associated 
infection in the ICU according to the Centres for Disease Control and Prevention 
definitions (central line-associated bloodstream infections, catheter-associated 
urinary tract infections, ventilator-associated pneumonia and surgical site infections), 
and 28- and 90-day mortality. 
2.7. Study design  
For each patient, the cytokine concentration after LPS stimulation was compared to 
the concentration in samples incubated without LPS (baseline), and expressed as a 
ratio (stimulated/baseline). A ratio above 1.5 at day 1 and day 7 was chosen as an 
arbitrary cut-off point, to reflect a potentially preserved response after LPS-
stimulation.  
First, the cytokine variations after stimulation were compared between septic patients 
and healthy controls. Then, the proportion of patients with persistent organ 
dysfunction at day 7 was compared between patients below and above the 1.5 ratio 
for each cytokine at day 1. Finally, the relationship between organ dysfunction and 
the temporal evolution of cytokine release after whole blood LPS-stimulation was 
studied. For this final analysis, only the patients with a ratio below 1.5 at day 1, for a 
given cytokine were considered. For each of these groups, the proportion of patients 
with persistent organ dysfunction at day 7 was compared between patients who 
recovered a ratio above 1.5 at day 7 and those who did not. 
 
2.8. Statistical Analysis 
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All statistical analysis was performed using PRISM 7 (GraphPad Software, La Jolla, 
Ca, USA). Quantitative data were expressed as median and interquartile ranges 
(IQR), while categorical data were expressed as absolute values and percentages. 
Quantitative data were compared using Mann-Whitney U test. Categorical data were 
compared using chi-square tests or Fisher’s exact test in case of non-parametric 
data. A two-sided p-value < 0.05 was considered statistically significant.  
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3. Results 
 
3.1. Patient characteristics 
A total of 49 patients were enrolled in the study, including 37 patients with septic 
shock (76%). Thirty-one patients (63%) were mechanically ventilated. The origin of 
sepsis was abdominal in 61% of the cases. The rate of appropriate first antimicrobial 
therapy was 89% and the median duration between hypotension and initiation of an 
effective antimicrobial therapy was 0 (0-30) minutes. Other patient characteristics are 
displayed in table 1. 
 
3.2. Cytokine release  
Median concentration of cytokine release with and without LPS-stimulation at day 1 
and day 7, in septic patients and healthy volunteers, are displayed in table 2. 
 
3.3. Comparison of the cytokine release after whole blood LPS-stimulation in 
septic patient with those in healthy controls  
At day 1 and day 7, the ratio of cytokine release after whole blood LPS-stimulation to 
cytokine release at baseline in septic patients were significantly lower than the same 
ratio in healthy controls (Figure 1).  
When considering only patients with samples available at day 1 and at day 7 (n=35 
except for IL-6 n=34), a significant increase was seen in this ratio between day 1 and 
day 7 for IL-1, IL-6 and IL-10 but not for TNF- (Figure 2). 
 
 
3.4. Persistent organ dysfunction at day 7 
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Considering IL-10 release, a significantly higher proportion of patients with a ratio 
below 1.5 at day 1 was found to have persistent organ dysfunction (SOFA score>= 2) 
at day 7 than patients with a ratio above 1.5 (13/24 vs 4/20 respectively, p=0.03). 
However, the proportion of patients with persistent organ dysfunction at day 7 was 
not significantly different between patients with a ratio below and above 1.5 for IL-1  
(8/19 vs 9/27 respectively, p >0.99), IL-6 (9/21 vs 7/24, p=0.12) or TNF- (11/27 vs 
6/18, p=0.38) release at day 1. Similarly, when considering cytokine release at day 7, 
there was no significant relationship between patients with a ratio below and above 
1.5 and organ dysfunction for any of the measured cytokines, including IL-10. 
 
3.5. Secondary outcomes 
Only three patients (6%) died within 28 days, five patients (10%) died within 90 days, 
and five patients (10%) developed healthcare-associated infection in the ICU. These 
outcomes were less common than expected, precluding further analysis. 
 
3.6. Relationship between persistent organ failure at day 7 and the temporal 
evolution of cytokine release after whole blood LPS-stimulation (figure 3) 
When considering only IL-10 release, patients whose ratio was below 1.5 at day 1 
and increased above 1.5 at day 7 were significantly less likely to have persistent 
organ dysfunction than patients who did not recover IL-10 release at day 7 (6/14 vs 
5/5, respectively p=0.045). However, no significant difference in organ dysfunction 
was found between patients whose ratio was below 1.5 at day 1 and increased 
above 1.5 at day 7 for IL-6 (3/10 vs 3/4, respectively p=0.25), IL-1 (5/10 vs 2/3 
respectively, p >0.99) or  TNF-  (3/9 vs 8/13 respectively, p=0.39). 
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4. Discussion 
We observed a significant and prolonged reduction of TNF-, IL-1, IL-6 and IL-10 
release after whole blood LPS-stimulation in septic patients compared to healthy 
controls. This reduction in TNF-, IL-1, IL-6 and IL-10 release likely reflects the well-
described phenomenon of LPS tolerance or immunoparalysis, in which circulating 
leukocytes in septic patients have a diminished ability to release additional cytokines 
[22,27]. We also observed that patients with low IL-10 release after LPS stimulation 
at day 1 had a higher rate of persistent organ dysfunction. Moreover, persistently low 
IL10 release was associated with higher proportion of organ dysfunction at day 7. 
The same kind of association was not observed with the other cytokines. 
The data available concerning the release of IL-10 after whole blood LPS-stimulation 
in septic patients are scarce and contradictory. While Marchant et al. found a 
decrease in IL-10 release in 10 patients with septic shock compared to healthy 
controls, Rigato and Salomao did not observe any differences in IL-10 release in 20 
septic patients (including 15 with septic shock) compared to healthy controls [20,21]. 
Four hours after experimental endotoxemia in healthy human volunteers, Kox et al. 
reported a 45% drop in peak IL-10 release after ex vivo LPS stimulation [28]. Other 
authors have reported that, while peripheral blood mononuclear cells (PBMCs) in 
septic patients released less IL-10 than in healthy controls after LPS stimulation, IL-
10 release from the monocytes of septic patients after LPS stimulation was higher 
than in healthy controls [29,30]. Finally, ex vivo stimulation of whole blood from septic 
patients, with intact Escherichia coli, leads to a depressed IL-10 release compared to 
healthy controls, but stimulation with intact Pseudomonas aeruginosa does not 
[21,23]. 
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It may be that a decreasing ability to release IL-10 in whole blood in response to ex 
vivo stimulation is the result of significant ongoing IL-10 production in vivo, and may 
reflect immunosuppression. This explanation is consistent with previous studies, 
which found that elevated plasma IL-10 concentrations were associated with 
mortality in severe sepsis and septic shock [31-34]. Elevated plasma IL-10 was also 
found to be associated with ICU acquired infections in severe sepsis and septic 
shock, although other authors did not find any associations [34,35]. In one study, IL-
10 release after LPS-stimulation in PBMCs was found to be higher in non-surviving 
septic patients, the opposite of the pattern that we observed [30]. This difference may 
be explained by our use of a whole blood stimulation assay, which allows the 
evaluation not only of PMBCs functionality, but also of other immune cells including 
granulocytes and platelets [36,37]. Furthermore, the use of whole blood maintains 
interactions between cellular elements that are required for cell viability, and avoids 
the potential influence of artificial medium on isolated cells [37]. 
We did not find any association between inflammatory cytokine release after whole 
blood LPS-stimulation at day 1 and persistent organ dysfunction. Several studies 
have previously evaluated TNF- release after whole blood LPS-stimulation and 
outcomes in septic patients with contradictory results. Ploder et al. reported that TNF-
 release after ex vivo stimulation in 19 patients with polytrauma and sepsis was 
lower in non-survivors than in survivors [15]. Similarly, in 52 critically ill children with 
Influenza, lower TNF- release upon ex vivo stimulation within 72 hours of ICU 
admission was associated with higher mortality and fewer ICU-free days [10]. Finally 
lower TNF- release was found to be associated with persistent organ dysfunction in 
102 septic children as well as in 24 septic adults [18,19]. In contrast, in 83 adults with 
severe sepsis, TNF- release at several time points was not found associated with 
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survival  or development of secondary infection [6]. Similarly, no association was 
found between TNF-, IL-6 or IL-1 release after whole blood LPS-stimulation in 
another population of 73 critically ill patient (including 47 septic patients) and 
subsequent development of ICU-acquired infections [17]. These discrepancies could 
be explained in part by the lack of standardisation of LPS-induced cytokine 
production assays. Indeed, TNF- release was found to be highly dependent on the 
source and concentration of LPS, duration and temperature of incubation, 
anticoagulation, and sample dilution [38]. As a result, increased standardisation of 
LPS stimulation assays is urgently required in order to improve the external validity of 
studies in this area. In our study, although the stimulation protocol was based on a 
previous study in COPD patients [39], LPS concentration was higher and incubation 
time longer than that often reported in studies performing whole blood LPS-
stimulation in septic patients. This study is, to the best of our knowledge, the first to 
report an association between low release of IL-10 after ex vivo whole blood LPS-
stimulation and persistent organ failure in a prospective cohort of severe sepsis 
patients. Moreover, the cytokine release was evaluated at two different time points to 
better reflect the dynamic process of inflammation in sepsis. However, several 
limitations must be underlined. First, as discussed above, our LPS-stimulation 
protocol differed in several points from the protocols generally used in septic patients, 
limiting the comparability of our data. Also, our septic population was older than the 
healthy volunteers, so the comparison could not be age-matched. This is relevant 
because older age is associated with a state of chronic inflammation, and impaired 
production of pro-inflammatory cytokines in response to lipopolysaccharide 
stimulation has been reported in the elderly [40,41]. However, human studies 
comparing levels of cytokine release between young and older septic patients 
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remains scarce and the data contradictory [41]. Additionally, our sample size is small, 
as our work was designed as a pilot study. Also, while our study population was 
severely ill, with 76% having septic shock, and high median SOFA and SAPS II 
scores, both the rates of mortality and healthcare associated infections were lower 
than typically reported [42-46]. These low rates precluded the use of these outcomes 
as secondary endpoints as previously planned.  Moreover, a monocentric design and 
the enrolment of mainly surgical (80%) patients limit the generalisation of our results. 
Further studies are needed to confirm our results in a larger and multicentre cohort 
with a higher ratio of medical patients and with additional endpoints.  
 
5. Conclusion 
 
Early low IL-10 release after ex vivo LPS stimulation of whole blood in sepsis, as well 
as persistent low IL-10 response over time, may be associated with persistent organ 
dysfunction. While these results will need to be confirmed in future studies, they do 
highlight the potential role of early IL-10 release and evolution of IL-10 release after 
ex vivo LPS stimulation of whole blood in sepsis as both a potential prognostic 
marker, and a potential means to stratify patients in clinical trials of 
immunomodulatory therapeutics. 
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 Figure legends 
Figure 1  
Comparison of the ratio of cytokine release after whole blood lipopolysaccharide-
stimulation to cytokine release at baseline at day 1 and day 7 between septic patients 
and healthy controls, A: Tumor Necrosis Factor(TNF)- (n=48 septic patients and 23 
healthy controls), B: Interleukin (IL)-1 (n=49 and 23 respectively), C: IL-6(n=48 and 
22 respectively) and D: IL-10 (n=47 and 23 respectively), Data presented as box-
plots with minimum to maximum value on a log-scale, Mann-Whitney U test  **** P 
<0.0001. 
 
Figure 2  
Evolution of the ratio of cytokine release after whole blood lipopolysaccharide-
stimulation to cytokine release at baseline between day 1 and day 7 (n=35, except 
IL6 n=34), A: Tumor Necrosis Factor(TNF)- B: Interleukin (IL)-1, C: IL-6 and D: IL-
10 , Median with interquartile range, Mann-Whitney U test * P=0.03,** P=0.01 and *** 
P=0.0005 . 
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 Table 1 Patient Characteristics (n=49) 
 
Age, years, median (IQR)                                      64 (54-70) 
Gender, (male) n (%)                                                                                      29 (59) 
MacCabe, n (%) 
A 
B 
C 
 
23 (47) 
23 (47) 
3 (6) 
Type of admission, n (%)            
Medical 
Surgical Emergency 
Surgical Scheduled 
 
10 (20) 
35 (71) 
4 (9) 
Septic Shock, n (%) 37 (76) 
Mechanical Ventilation, n (%) 31 (63) 
Renal Replacement Therapy, n (%) 7 (14) 
Low-Dose Corticosteroids use, n (%) 8 (16) 
Site of Initial Infection, n (%)     
Intra-Abdominal 
Urinary Tract 
Lung 
Others 
 
30 (61) 
7 (15) 
6 (12) 
6 (12) 
Type of Infection, n (%) 
Gram-positive  
Gram-negative 
Fungi 
 
30 (61) 
25 (51) 
6 (12) 
Source of Initial Infection, n (%) 
Community-acquired 
Health-care associated 
 
23 (47) 
26 (53) 
Healthcare Associated Secondary Infection ICU-Acquired, n (%) 
SSI 
VAP 
5 (10) 
3 
2 
SAPS II, median (IQR)                                   44 (35-56) 
SOFA score, median (IQR) 
Day 1 
Day 7 n=46 
 
7 (5-8) 
1 (0-3) 
White Blood Cells day 1, 109/L, median (IQR) n=46 15.9 (10.8-20.8) 
White Blood Cells day 7, 109/L, median (IQR) n=35 14.7 (10.7-18.4) 
ICU Free-Days at Day 28, median (IQR) 22 (16-25) 
Hospital Mortality, n (%) 2 (4) 
Day 90 Mortality, n (%) 5 (10) 
ICU=Intensive Care Unit, SAPS= Simplified Acute Physiology Score, SOFA= Sequential Organ 
Failure Assessment, SSI= Surgical Site Infection, VAP=Ventilator-Associated Pneumonia  
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Table 2 Median concentrations (pg/mL) of cytokine release in whole blood without (baseline) and with LPS stimulation in septic patients at day 
1 and day 7, and in healthy volunteers. 
 Day 1 Day 7 Healthy Volunteers 
 Baseline, n=49 LPS Baseline, n=35 LPS Baseline, n=23 LPS 
TNF 
44.57               
(5.50-204.91), 
n=48 
129.26           
(20.09-391.77) 
127.77                
(5.50-223.76) 
305.77          
(71.10-851.41) 
5.50                 
(5.50-122.25) 
2,461.60 
(1,690.80-
6,525.80) 
IL1 
2.03                 
(1.00-37.84) 
50.80                 
(1.00-251.93) 
136.70           
(11.59-369.55) 
904.02         
(341.09-1,672.65) 
1.00                  
(1.00-103.45) 
3,998.20 
(2.637.00-
5,883.55) 
IL6 
1,805.35         
(404.9-8,326.23), 
n=48 
4,440.10      
(1,284.15-
9,839.04) 
4,868.25   
(1,230.52-
8,734.45) 
12,194.90   
(7,039.39-
23,868.50) 
9.05                   
(0.70-311.55), 
n=22 
23,460.80 
(1,6330.23-
35,519.53) 
IL10 
119.01          
(43.43-373.88), 
n=47 
222.51            
(98.47-452.47) 
136.42           
(52.99-271.14) 
451.27        
(204.64-626.72) 
3.90                 
(3.90-140.80) 
1,000.20    
(685.10-1,606.30) 
Data are presented as median (IQR). IL=Interleukin, LPS=Lipopolysaccharide, TNF= Tumor Necrosis Factor. 
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